R X Sample Solutions

Xellia Pharmaceuticals is a global leader in manufacturing fermentation-based non-beta-lactam anti-infectives, providing essential active pharmaceutical ingredients (APIs) and Finished Dosage Forms (FDFs) to over 500 pharmaceutical companies across 80 countries. Recognized by the World Health Organization and the European Union, their products play a crucial role in combating severe infections and addressing antimicrobial resistance. Headquartered in Copenhagen, Denmark, Xellia boasts a rich legacy of over 120 years in the pharmaceutical industry, with manufacturing sites in Denmark, Hungary, and China. As the sole European manufacturer of several of its products, the company maintains a strong global presence with R&D and commercial operations spanning eight additional locations worldwide. Generated from the website

Established in 1923, Diosynth Biotechnology operates a manufacturing plant that utilizes cell culture and microbial production processes to manufacture drugs. The company offers a range of recombinant therapeutic proteins and vaccines for preclinical, clinical and commercial purposes. Its analytical development team works on various techniques, such as DNA sequencing, biophysical characterization, capillary electrophoresis and mass spectrometry. Diosynth Biotechnology manufactures products using mammalian, insect and microbial expression systems. In addition, the company s cell culture development technology utilizes hybridomas, murine myelomas and human cell lines. It undertakes real time stability studies for products, intermediates and reference standards. Diosynth Biotechnology maintains a location in Morrisville, N.C.

Founded in 2002, Chimerix is a privately held biotechnology company that creates and develops orally available medicines from bioactive molecules. Its applications of proprietary technology enhance oral availability, stabilize drug in plasma and facilitates the delivery of drugs into targeted tissues. Chimerix offers drugs that can be modified to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse reactions. Its technology also enables discovery of new drugs from molecules with chemical properties that would otherwise be unsuitable for pharmaceutical development. In addition, Chimerix applies its technology towards discovery and the development of oral drugs for the treatment of smallpox, drug-resistant HIV infection and viral hepatitis. The company is located in Durham, N.C.